himalaya: study of tremelimumab and durvalumab as first-line therapy in patients with uhcc
Published 2 years ago • 868 plays • Length 7:48Download video MP4
Download video MP3
Similar videos
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
-
3:34
himalaya: does underlying liver function impact efficacy of tremelimumab plus durvalumab for hcc?
-
2:35
himalaya trial: asian subgroup results
-
7:47
combination tremelimumab and durvalumab in hcc
-
2:33
emerald-3: tremelimumab durvalumab with or without lenvatinib combined with tace in hcc
-
3:26
infinty: tremelimumab and durvalumab in msi-high gc/gejc
-
3:57
katie kelley, md, discusses fitting tremelimumab durvalumab into hcc treatment algorithms
-
3:55
the use of immunotherapy in hcc – efficacy and safety
-
0:52
himalaya: outcomes by comorbidities with stride in hepatocellular carcinoma
-
2:12
dutreneo: durvalumab and tremelimumab vs chemo
-
3:35
asco 2020: himalaya trial for advanced hcc
-
28:59
evolving options for the treatment of hcc with immunotherapy and liver directed therapy (ldt)
-
1:15
montblanc: sequential or up-front durvalumab, tremelimumab, bevacizumab in unresectable hcc
-
8:28
debate: optimal first-line therapy in unresectable hcc? - mki followed by immunotherapy
-
1:02
evaluating real-world efficacy of durvalumab and tremelimumab in hcc
-
3:29
immunotherapy could signal a ‘change in the treatment paradigm’ for patients with hcc
-
2:19
should hcc be treated with locoregional or systemic therapies?
-
4:53
checkpoint inhibition in hepatocellular carcinoma